Approaches to gene therapy with sodium/iodide symporter.
Since cloning and characterization of the sodium iodide symporter (NIS) gene, several investigators explored the possibility of a novel cytoreductive gene therapy strategy based on NIS gene transfer into non-thyroidal tumor cells followed by radioiodine therapy. NIS gene transfer has been shown to be capable of inducing radioiodine accumulation in vitro and in vivo in several non-thyroidal cancer cell lines. Following PSA promoter-mediated NIS gene delivery we were able to demonstrate prostate-specific iodide accumulation in prostate cancer cells that was high enough to elicit a therapeutic response of 131-I in vitro and in vivo. This study clearly demonstrates the potential of NIS as a novel therapeutic gene for non-thyroidal cancers, in particular prostate cancer.
Spitzweg
C
C
Division of Endocrinology, Mayo Clinic & Medical School, Rochester, MN 55905, USA. spitzweg.christine@mayo.edu
Morris
J C
JC
D000818:Animals; D002460:Cell Line; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D007455:Iodine / Q000378:metabolism*; D007457:Iodine Radioisotopes / Q000378:metabolism / Q000627:therapeutic use*; D008297:Male; D008958:Models, Molecular; D011401:Promoter Regions, Genetic; D017430:Prostate-Specific Antigen / Q000235:genetics; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000628:therapy; D027981:Symporters / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D014407:Tumor Cells, Cultured; D000099209:Sodium-Iodide Symporters
D007455:Iodine; D007457:Iodine Radioisotopes; D017430:Prostate-Specific Antigen; D027981:Symporters; D000099209:Sodium-Iodide Symporters